Invesco Ltd. increased its position in Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.9% during the 1st quarter, Holdings Channel reports. The firm owned 2,109,259 shares of the company’s stock after acquiring an additional 17,974 shares during the quarter. Invesco Ltd. owned about 0.08% of Oxford Immunotec Global worth $19,531,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Senvest Management LLC lifted its holdings in Oxford Immunotec Global by 89.6% during the first quarter. Senvest Management LLC now owns 1,325,854 shares of the company’s stock worth $12,277,000 after buying an additional 626,469 shares during the period. Penn Capital Management Co. Inc. lifted its holdings in Oxford Immunotec Global by 98.7% during the fourth quarter. Penn Capital Management Co. Inc. now owns 769,055 shares of the company’s stock worth $12,766,000 after buying an additional 382,035 shares during the period. Alyeska Investment Group L.P. lifted its holdings in Oxford Immunotec Global by 11.7% during the first quarter. Alyeska Investment Group L.P. now owns 1,451,644 shares of the company’s stock worth $13,442,000 after buying an additional 152,144 shares during the period. Knights of Columbus Asset Advisors LLC purchased a new stake in Oxford Immunotec Global during the fourth quarter worth $2,140,000. Finally, Oppenheimer & Co. Inc. lifted its holdings in shares of Oxford Immunotec Global by 144.7% during the 1st quarter. Oppenheimer & Co. Inc. now owns 172,300 shares of the company’s stock valued at $1,595,000 after purchasing an additional 101,900 shares during the last quarter. 93.51% of the stock is currently owned by institutional investors.
OXFD stock opened at $13.00 on Wednesday. The company has a current ratio of 14.30, a quick ratio of 13.53 and a debt-to-equity ratio of 0.04. Oxford Immunotec Global PLC has a 12-month low of $8.37 and a 12-month high of $17.77. The stock has a market cap of $339.37 million, a price-to-earnings ratio of -54.17 and a beta of 1.06. The business’s 50-day moving average is $12.83 and its 200 day moving average is $13.47.
Several analysts have recently commented on the company. ValuEngine upgraded Oxford Immunotec Global from a “hold” rating to a “buy” rating in a report on Wednesday, May 6th. Zacks Investment Research lowered Oxford Immunotec Global from a “buy” rating to a “hold” rating in a report on Thursday, May 7th. Finally, BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Friday, June 12th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $18.33.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith purchased 26,000 shares of the company’s stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $11.45 per share, for a total transaction of $297,700.00. Following the completion of the purchase, the chief executive officer now directly owns 358,700 shares in the company, valued at approximately $4,107,115. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Patrick J. Balthrop purchased 4,000 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $12.53 per share, with a total value of $50,120.00. Following the purchase, the director now owns 4,000 shares of the company’s stock, valued at $50,120. The disclosure for this purchase can be found here. Insiders purchased a total of 32,075 shares of company stock valued at $370,126 in the last quarter. 4.33% of the stock is owned by insiders.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Article: What is Elliott Wave theory?
Want to see what other hedge funds are holding OXFD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oxford Immunotec Global PLC (NASDAQ:OXFD).
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.